New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: Modulation by endogenous omega-3 fatty acid-derived lipid mediators

Frontiers in Immunology

Volumn 2, Issue OCT, 2011, Pages

  Clària, Joan ^a,b,c   González Périz, Ana ^a,c   López Vicario, Cristina ^a   Rius, Bibiana ^a   Titos, Esther ^a,c  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adipocytes; Docosahexaenoic acid; Kupffer cells; M2 macrophages; Obesity; Resolvins

Indexed keywords

EID: 84867940403     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2011.00049     Document Type: Review

References (79)

1. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J. N., Petasis, N. A., Blumberg, R. S., and Serhan, C. N. (2005). Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acidinduced colitis. Proc. Natl. Acad. Sci. U.S.A. 102, 7671-7676.
2. Baffy, G. (2009). Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J. Hepatol. 51, 212-223.
3. Bannenberg, G., and Serhan, C. N. (2010). Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim. Biophys. Acta 1801, 1260-1273.
4. Bassaganya-Riera, J., Misyak, S., Guri, A. J., and Hontecillas, R. (2009). PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation. Cell. Immunol. 258, 138-146.
5. Bataller, R., and Brenner, D. A. (2005). Liver fibrosis. J. Clin. Invest. 115, 209-218.
6. Bilzer, M., Roggel, F., and Gerbes, A. L. (2006). Role of Kupffer cells in host defense and liver disease. Liver Int. 26, 1175-1186.
7. Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J. L., Bouloumie, A., Barbatelli, G., Cinti, S., Svensson, P. A., Barsh, G. S., Zucker, J. D., Basdevant, A., Langin, D., and Clement, K. (2005). Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgeryinduced weight loss. Diabetes 54, 2277-2286.
8. De Caterina, R., Madonna, R., Bertolotto, A., and Schmidt, E. B. (2007). n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care 30, 1012-1026.
9. Decker, K. (1990). Biologically active products of stimulated liver macrophages (Kupffer cells). Eur. J. Biochem. 192, 245-261.
10. Devalaraja, M. N., Mcclain, C. J., Barve, S., Vaddi, K., and Hill, D. B. (1999). Increased monocyte MCP-1 production in acute alcoholic hepatitis. Cytokine 11, 875-881.
11. Dinarello, C. A. (2010). Antiinflammatory agents: present and future. Cell 140, 935-950.
12. Domínguez, M., Miquel, R., Colmenero, J., Moreno, M., García-Pagán, J. C., Bosch, J., Arroyo, V., Ginès, P., Caballeria, J., and Bataller, R. (2009). Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 136, 1639-1650.
13. Dona, M., Fredman, G., Schwab, J. M., Chiang, N., Arita, M., Goodarzi, A., Cheng, G., von Andrian, U. H., and Serhan, C. N. (2008). Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112, 848-855.
14. Ellett, J. D., Atkinson, C., Evans, Z. P., Amani, Z., Balish, E., Schmidt, M. G., van, Rooijen N., Schnellmann, R. G., and Chavin, K. D. (2010). Murine Kupffer cells are protective in total hepatic ischemia/reperfusion injury with bowel congestion through IL-10. J. Immunol. 184, 5849-5858.
15. Endres, S., Ghorbani, R., Kelley, V. E., Georgilis, K., Lonnemann, G., van der Meer, J. W., Cannon, J. G., Rogers,T. S.,Klempner,M. S.,Weber, P. C., Schaefer, E. J., Wolff, S. M., and Dinarello, M. D. (1989). The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 320, 265-271.
16. Ferrante, A. W. Jr. (2007). Obesityinduced inflammation: a metabolic dialogue in the language of inflammation. J. Intern. Med. 262, 408-414.
17. González-Périz, A., Horrillo, R., Ferré, N., Gronert, K., Dong, B., MoránSalvador, E., Titos, E., MartínezClemente, M., López-Parra, M., Arroyo, V., and Clària, J. (2009). Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 23, 1946-1957.
18. González-Périz, A., Planagumà, A., Gronert,K.,Miquel,R.,López-Parra, M., Titos, E., Horrillo, R., Ferré, N., Deulofeu, R., Arroyo, V., Rodés, J., and Clària, J. (2006). Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 20, 2537-2539.
19. Gordon, S. (2003). Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35.
20. Gordon, S., and Taylor, P. R. (2005). Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964.
21. Gronert, K., Maheshwari, N., Khan, N., Hassan, I. R., Dunn, M., and Laniado, S. M. (2005). A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 280, 15267-15278.
22. Haas-Stapleton, E. J., Lu, Y., Hong, S., Arita, M., Favoreto, S., Nigam, S., Serhan, C. N., and Agabian, N. (2007). Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS ONE 2, e1316. doi:10.1371/journal.pone.0001316
23. Haworth, O., Cernadas, M., Yang, R., Serhan, C. N., and Levy, B. D. (2008). Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9, 873-879.
24. Hellmann, J., Tang, Y., Kosuri, M., Bhatnagar, A., and Spite, M. (2011). Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 25, 2399-2407.
25. Hong, S., Gronert, K., Devchand, P. R., Moussignac, R. L., and Serhan, C. N. (2003). Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in antiinflammation. J. Biol. Chem. 278, 14677-14687.
26. Horrillo, R., González-Périz, A., Martínez-Clemente, M., López Parra, M., Ferré, N., Titos, E., Morán-Salvador, E., Deulofeu, R., Arroyo, V., and Clària, J. (2010). 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J. Immunol. 184, 3978-3987.
27. Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature 444, 860-867.
28. Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., and Spiegelman, B. M. (1996). IRS1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alphaand obesity-induced insulin resistance. Science 271, 665-668.
29. Kim, J. K. (2006). Fat uses a TOLLroad to connect inflammation and diabetes. Cell Metab. 4, 417-419.
30. Kodama, Y., Kisseleva, T., Iwaisako, K., Miura, K., Taura, K., De Minicis, S., Osterreicher, C. H., Schnabl, B., Seki, E., and Brenner, D. A. (2009). c-Jun N-terminal kinase1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 137, 1467-1477.
31. Lanthier, N., Molendi-Coste, O., Horsmans, Y., van Rooijen, N., Cani, P. D., and Leclercq, I. A. (2010). Kupffer cell activation is a causal factor for hepatic insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G107-G116.
32. Leifeld, L., Cheng, S., Ramakers, J., Dumoulin, F. L., Trautwein, C., Sauerbruch, T., and Spengler, U. (2002). Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology 36, 1001-1008.
33. Lesniewski, L. A., Hosch, S. E., Neels, J. G., de Luca, C., Pashmforoush, M., Lumeng, C. N., Chiang, S. H., Scadeng, M., Saltiel, A. R., and Olefsky, J. M. (2007). Bone marrowspecific Cap gene deletion protects against high-fat diet-induced insulin resistance. Nat. Med. 13, 455-462.
34. Li, P., Lu, M., Nguyen, M. T., Bae, E. J., Chapman, J., Feng, D., Hawkins, M., Pessin, J. E., Sears, D. D., Nguyen, A. K., Amidi, A., Watkins, S. M., Nguyen, U., and Olefsky, J. M. (2010). Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J. Biol. Chem. 285, 15333-15345.
35. Lieber, C. S. (1997). Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv. Pharmacol. 38, 601-628.
36. Lumeng, C. N., Bodzin, J. L., and Saltiel, A. R. (2007). Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184.
37. Lumeng, C. N., and Saltiel, A. R. (2011). Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121, 2111-2117.
38. Mantovani, A., Sica, A., and Locati, M. (2007). New vistas on macrophage differentiation and activation. Eur. J. Immunol. 37, 14-16.
39. Martínez, F. O., Helming, L., and Gordon, S. (2009). Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483.
40. Martínez, F. O., Sica, A., Mantovani, A., and Locati, M. (2008). Macrophage activation and polarization. Front. Biosci. 13, 453-461.
41. Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., and Seki, E. (2010). Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139, 323-324.
42. Mosser, D. M., and Edwards, J. P. (2008). Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969.
43. Muriel, P. (2009). Role of free radicals in liver diseases. Hepatol. Int. 3, 526-536.
44. Nettleton, J. A., and Katz, R. (2005). n3 Long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J. Am. Diet. Assoc. 105, 428-440.
45. Neuman, M. G., Sha, K., Esguerra, R., Zakhari, S., Winkler, R. E., Hilzenrat, N., Wyse, J., Cooper, C. L., Seth, D., Gorrell, M. D., Haber, P. S., McCaughan, G. W., Leo, M. A., Lieber, C. S., Voiculescu, M., Buzatu, E., Ionescu, C., Dudas, J., Saile, B., and Ramadori, G. (2008). Inflammation and repair in viral hepatitis C. Dig. Dis. Sci. 53, 1468-1487.
46. Nguyen, M. T., Favelyukis, S., Nguyen, A. K., Reichart, D., Scott, P. A., Jenn, A., Liu-Bryan, R., Glass, C. K., Neels, J. G., and Olefsky, J. M. (2007). A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNKdependent pathways. J. Biol. Chem. 282, 35279-35292.
47. Odegaard, J. I., Ricardo-Gonzalez, R. R., Red, E. A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., and Chawla, A. (2008). Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 7, 496-507.
48. Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., and Olefsky, J. M. (2010). GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687-698.
49. Olefsky, J. M., and Glass, C. K. (2010). Macrophages, inflammation, and insulin resistance. Annu.Rev.Physiol. 72, 219-246.
50. Ouchi, N., Parker, J. L., Lugus, J. J., and Walsh, K. (2011). Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85-97.
51. Patsouris, D., Li, P. P., Thapar, D., Chapman, J., Olefsky, J. M., and Neels, J. G. (2008). Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8, 301-309.
52. Pinzani, M. (2002). PDGF and signal transduction in hepatic stellate cells. Front. Biosci. 7, 1720.
53. Planagumà, A., Clària, J., Miquel, R., López-Parra, M., Titos, E., Masferrer, J. L., Arroyo, V., and Rodés, J. (2005). The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 19, 1120-1122.
54. Quiroga, J., and Prieto, J. (1993). Liver cytoprotection by prostaglandins. Pharmacol. Ther. 58, 67-91.
55. Ramadori, G., and Armbrust, T. (2001). Cytokines in the liver. Eur. J. Gastroenterol. Hepatol. 13, 777-784.
56. Ramadori, G., Moriconi, F., Malik, I., and Dudas, J. (2008). Physiology and pathophysiology of liver inflammation, damage and repair. J. Physiol. Pharmacol. 59(Suppl. 1), 107-117.
57. Sanyal, A. J. (2005). Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2, 46-53.
58. Schif-Zuck, S., Gross, N., Assi, S., Rostoker, R., Serhan, C. N., and Ariel, A. (2011). Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41, 366-379.
59. Schwab, J. M., Chiang, N., Arita, M., and Serhan, C. N. (2007). Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869-874.
60. Scotton, C. J., Martinez, F. O., Smelt, M. J., Sironi, M., Locati, M., Mantovani, A., and Sozzani, S. (2005). Transcriptional profiling reveals complex regulation of the monocyte IL-1 beta system by IL-13. J. Immunol. 174, 834-845.
61. Serhan, C. N. (2011). The resolution of inflammation: the devil in the flask and in the details. FASEB J. 25, 1441-1448.
62. Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A., Perretti, M., Rossi, A. G., and Wallace, J. L. (2007). Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325-332.
63. Serhan, C. N., Chiang, N., and Van Dyke, T. E. (2008). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349-361.
64. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., and Gronert, K. (2000). Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204.
65. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick,G.,and Moussignac,R. L. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037.
66. Shapiro, H., Tehilla, M., Attal-Singer, J., Bruck, R., Luzzatti, R., and Singer, P. (2011). The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin. Nutr. 30, 6-19.
67. Shoelson, S. E., Lee, J., and Goldfine, A. B. (2006). Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801.
68. Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower,R. J.,Perretti,M.,and Serhan, C. N. (2009). Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287-1291.
69. Tabas, I. (2010). Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36-46.
70. Takeuchi, D., Yoshidome, H., Kato, A., Ito, H., Kimura, F., Shimizu, H., Ohtsuka, M., Morita, Y., and Miyazaki, M. (2004). Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology 39, 699-710.
71. Taub, R. (2004). Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell Biol. 5, 836-847.
72. Tilg, H., and Moschen, A. R. (2008). Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab. 19, 371-379.
73. Titos, E., Clària, J., Bataller, R., BoschMarcé, M., Ginès, P., Jiménez, W., Arroyo, V., Rivera, F., and Rodés, J. (2000). Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 119, 794-805.
74. Titos, E., Clària, J., Planagumà, A., López-Parra, M., González-Périz,A., Gaya, J., Miquel, R., Arroyo, V., and Rodés, J. (2005). Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J. Leukoc. Biol. 78, 871-878.
75. Titos, E., Clària, J., Planagumà, A., López-Parra, M., Villamor, N., Parrizas, M., Carrió, A., Miquel, R., Jiménez, W., Arroyo, V., Rivera, F., and Rodés, J. (2003). Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB J. 17, 1745-1747.
76. Titos, E., Rius, B., González-Périz, A., López-Vicario, C., Morán-Salvador, E., Martínez-Clemente, M., Arroyo, V., and Clària, J. (2011). Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. (in press).
77. Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., and Ferrante, A. W. Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808.
78. Wellen, K. E., and Hotamisligil, G. S. (2003). Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112, 1785-1788.
79. Wynn, T. A., and Barron, L. (2010). Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 30, 245-257.